Role of Chlamydia infection in the pathogenesis of atherosclerotic plaques in HIV-1-positive patients

In Vivo

Volumn 20, Issue 3, 2006, Pages 409-414

  Maggi, Paolo ^a   Monno, Rosanna ^a   Chirianni, Antonio ^b   Gargiulo, Miriam ^b   Carito, Valentina ^a   Fumarola, Luciana ^a   Perilli, Francesco ^a   Lillo, Antonio ^a   Bellacosa, Chiara ^a   Panebianco, Annarita ^a   Epifani, Giuseppe ^a   Regina, Guido ^a  

^a UNIVERSITY OF BARI   (Italy)

^b AO Dei Colli Hospital for Infectious Diseases D Cotugno   (Italy)

Author keywords

Atherosclerosis; Carotid; Chlamydia pneumoniae; Colour Doppler ultrasonography; Protease inhibitors

Indexed keywords

BACTERIUM ANTIBODY; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; PROTEINASE INHIBITOR; RHESUS C ANTIBODY; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; ATHEROGENESIS; ATHEROSCLEROTIC PLAQUE; BLOOD ANALYSIS; CAROTID ARTERY; CHLAMYDIA TRACHOMATIS; CHLAMYDIASIS; CHLAMYDOPHILA PSITTACI; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOFLUORESCENCE; IMMUNOGLOBULIN BLOOD LEVEL; INTERVENING VARIABLE; MAJOR CLINICAL STUDY; MALE; RISK ASSESSMENT; RISK FACTOR; STATISTICAL SIGNIFICANCE;

EID: 33646833929     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Carr A, Samaras K, Chisholm DJ and Cooper DA: Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia and insulin resistance. Lancet 351: 1881-1883, 1998.
2. Martinez E and Gatell J: Metabolic abnormalities and use of HIV-1 protease inhibitors. Lancet 352: 821-822, 1998.
3. Yanovski JA, Miller KD, Kino T et al: Endocrine and metabolic evaluation of human immunodeficiency virus-infected patients with evidence of protease inhibitor-associated lipodystrophy. J Clin Endocrinol Metab 84: 1925-1931, 1999.
4. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ and Cooper DA: Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 353: 2093-2099, 1999.
5. Henry K, Melroe H, Huebsch J et al: Severe premature coronary artery disease with protease inhibitors. Lancet 351: 1328, 1998.
6. Behrens G, Shmidt H, Meyer D, Stoll M and Schmidt RE: Vascular complications associated with use of HIV protease inhibitors. Lancet 351: 1958, 1998.
7. Vittecoq D, Escaut L and Monsuez JJ: Vascular complications associated with use of HIV protease inhibitors. Lancet 351: 1959, 1998.
8. Laurence J: Vascular complications associated with use of HIV protease inhibitors. Lancet 351: 1960, 1998.
9. Maggi P, Fiorentino G, Saracino A et al: Precocious lesions of the carotid vessels in HIV-1 patients treated with protease inhibitors. Antiviral Ther 4(S 2): 54-55, 1999.
10. Maggi P, Serio G, Epifani G et al: Premature lesions of the carotid vessels in HIV-1-infected patients treated with protease inhibitors. AIDS 14: 123-128, 2000.
11. Maggi P, Fiorentino G, Epifani G et al: Premature vascular lesions in HIV-positive patients: a clockwork bomb that will explode? AIDS 16: 947-948, 2002.
12. Maggi P, Lillo A, Perilli F, Maserati R and Chirianni A: Colour-Doppler ultrasonography of carotid vessels in patients treated with antiretroviral therapy: a comparative study. AIDS 2004, in press.
13. Kuo C-C, Jackson LA, Campbell LA and Grayston JT: Chlamydia pneumoniae. Clin Microbiol Rev 8: 451-461, 1995.
14. Monno R, De Vito D, Losito G et al: Chlamydia pneumoniae in community - acquired pneumonia: seven years of experience. J Infect 45: 135-138, 2002.
15. Resta O, Monno R, Saracino A, Leone E, Gramiccioni E and Fumarola D: Chlamydia pneumoniae infection in Italian patients. Monadi Arch Chest Dis 50: 173-176, 1996.
16. Comandini UV, Maggi P, Santopadre P, Monno R, Angarano G and Vullo V: Chlamydia pneumoniae respiratory infections among patients infected with the human immunodeficiency virus. Eur J Clin Microbiol Infect Dis 16: 720-726, 1997.
17. Grayston JT: Background and current knowledge of Chlamydia pneumoniae and atherosclerosis. J Infect Dis 181(Suppl 3): S 402-410, 2000.
18. Lindholt JS, Fasting H, Henneberg EW and Osstergaad L: A review of Chlamydia pneumoniae and atherosclerosis. Eur J Vasc Surg 17: 283-289, 1999.
19. Boman J and Hammerschlag MR: Chlamydia pneumoniae and atherosclerosis: critical assessment of diagnostic methods and relevance to treatment studies. Clin Microbiol Rev 15: 1-20, 2002.
20. Saikku P: Epidemiological association of Chlamydia pneumoniae and atherosclerosis: the initial serologic observation and more. J Infect Dis 181(Suppl 3): S 311-413, 2000.
21. Ngeh J, Anand V and Gupta S: Chlamydia pneumoniae and atherosclerosis - what we know and what we don't. Clin Microbiol Infect 8: 2-13, 2002.
22. Wang S: The microimmunofluorescence test for C. pneumoniae infection: technique and interpretation. J Infect Dis 81: S 421-425, 2000.
23. Movahed MR: Infection with C. pneumoniae and atherosclerosis: a review. JSC Med Assoc 95: 303-308, 1999.
24. Hirashima Y, Kuwayama N, Kubo M, Origasa H and Endo S: Chlamydia pneumoniae infection is not involved in carotid artery stenosis. Atherosclerosis 163: 165-168, 2002.
25. Byrne GI and Kalayoglu MK: C. pneumoniae and atherosclerosis: links to the disease process. Am Heart J 1138: S 488-495, 1999.
26. Grandaliano G, Pertosa G, Manno C et al: The role of chronic infections and dialytic membrane biocompatibility on the development of atherosclerosis in hemodialysis. 38th Congress of the European Renal Association European Dialysis and Transplant Association, Jan 24-27, Wien, Austria, pp. 195, 2001.
27. Esposito G, Blasi F, Allegra L et al: Demonstration of viable C. pneumoniae in atherosclerotic plaques of carotid arteries by reverse transcriptase polymerase chain reaction. Ann Vasc Surg 13: 421-425, 1999.